search
Back to results

Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device

Primary Purpose

Spinal Stenosis

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
VerteLoc
Sponsored by
VG Innovations, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Stenosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
  2. Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
  3. Are skeletally mature, and are at least 18 years of age;
  4. If female, are not pregnant;
  5. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion Criteria:

  1. Previous surgery at the target or adjacent vertebral levels;
  2. More than two intervertebral levels to be treated by the laminectomy procedure;
  3. Found to be inappropriate candidates for facet fixation using the VerteLoc system;
  4. Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
  5. Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
  6. Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
  7. Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
  8. BMI >40% ;
  9. History of tobacco smoking within the past 6 months;
  10. Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
  11. Are participating in any other clinical trial.

Sites / Locations

  • Genesys Regional Medical Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Single Arm Study

Arm Description

All patients will receive treatment

Outcomes

Primary Outcome Measures

Fusion grade at 12 month follow-up using CT scans
Fusion grade at 12 month follow-up using CT scans with a grading system based on: Complete fusion; Partial fusion; No fusion;

Secondary Outcome Measures

Subject success / Clinical outcome
Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score.

Full Information

First Posted
July 1, 2013
Last Updated
March 14, 2018
Sponsor
VG Innovations, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01892878
Brief Title
Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device
Official Title
A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Withdrawn
Study Start Date
July 2013 (undefined)
Primary Completion Date
July 2015 (Anticipated)
Study Completion Date
January 1, 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VG Innovations, LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this clinical study is to evaluate fusion of the facet joints in a prospective cohort of patients utilizing the VerteLoc facet fixation device in patients receiving lumbar laminectomy (L1-S1), without ancillary stabilization devices such as pedicle and transfacet screws.
Detailed Description
Study Design: Non-randomized, prospective, single arm clinical trial Patient Population and Sample Size: Patients (n=25) from up to 2 clinical site, who have been medically evaluated, found appropriate for, and have agreed to treatment by lumbar decompressive laminectomy and facet fixation, including unilateral and/or bilateral posterolateral fusion according to accepted medical standards. Objectives: The primary objective of this study is to: Evaluate the fusion status of facet joints following laminectomy and facet fixation using the VerteLoc system in combination with unilateral and/or bilateral posterolateral fusion. Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at 2-3 weeks, 3 months, and 12 months. The secondary objectives of this study are to: Explore the effect of preoperative bone density on facet fusion status; Assess the ease of use of the VerteLoc system; Record operative time using the VerteLoc system; Monitor the occurrence of adverse events related or possibly related to the use of the VerteLoc system; Monitor the occurrence of subsequent surgical intervention at the target level(s). Subject success/Clinical outcome (Assess additional improvement criteria) Evaluate Fusion rate in relations to DEXA value Inclusion Criteria: Candidates must meet ALL of the following: Have provided consent for research by signing the Institutional Review Board approved Informed Consent; Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care; Are skeletally mature, and are at least 18 years of age; If female, are not pregnant; Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation. Exclusion Criteria: Previous surgery at the target or adjacent vertebral levels; More than two intervertebral levels to be treated by the laminectomy procedure; Found to be inappropriate candidates for facet fixation using the VerteLoc system; Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables; Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses, Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery; Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results; BMI >40% ; History of tobacco smoking within the past 6 months; Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study; Are participating in any other clinical trial. Study Duration : 12 months Study Outcomes: The primary study outcomes of this study are: Fusion grade at 12 month follow-up using CT scans with a grading system based on: Complete fusion; Partial fusion; No fusion; Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at: 2-3 weeks 3 months 12 months. The secondary outcomes of this study are: Statistical correlation of DEXA scan bone mass density score to CT and radiographic fusion status; Surgeon opinion of "ease of use" utilizing the VerteLoc system (0-10); Operative time (minutes) from surgical access to completion of device placement Occurrence and prevalence of adverse events related or possibly related to the use of the VerteLoc System; Occurrence of subsequent surgical intervention at the target level(s). Study Assessments Intraoperative: Post-placement radiograph; 12 months: A/P and lateral flexion and extension lumbar radiograph and lumbar CT scan. Statistical Analysis • Student t-tests

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Stenosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single Arm Study
Arm Type
Other
Arm Description
All patients will receive treatment
Intervention Type
Procedure
Intervention Name(s)
VerteLoc
Intervention Description
Single Arm
Primary Outcome Measure Information:
Title
Fusion grade at 12 month follow-up using CT scans
Description
Fusion grade at 12 month follow-up using CT scans with a grading system based on: Complete fusion; Partial fusion; No fusion;
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Subject success / Clinical outcome
Description
Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score.
Time Frame
2-3 weeks, 3 months and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have provided consent for research by signing the Institutional Review Board approved Informed Consent; Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care; Are skeletally mature, and are at least 18 years of age; If female, are not pregnant; Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation. Exclusion Criteria: Previous surgery at the target or adjacent vertebral levels; More than two intervertebral levels to be treated by the laminectomy procedure; Found to be inappropriate candidates for facet fixation using the VerteLoc system; Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables; Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses, Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery; Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results; BMI >40% ; History of tobacco smoking within the past 6 months; Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study; Are participating in any other clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Guyot, MD
Organizational Affiliation
Ascension Genesys Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Genesys Regional Medical Center
City
Grand Blanc
State/Province
Michigan
ZIP/Postal Code
48439
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device

We'll reach out to this number within 24 hrs